Ewing’s Sarcoma Family of Tumors (EWST)

Note: This section is used with permission from the author, Edward Y. Cheng, M.D., Mairs Family Professor, Department of Orthopaedic Surgery, University of Minnesota Cancer Center, RISF Board member and was originally in the Journal of the American Academy of Orthopaedic Surgeons, October 2004. For the the full article, including figures, click here.


This is a cancerous (malignant) tumor. It usually begins growing initially in a bone. Occasionally, it also begins in the soft tissues (extraosseous Ewing’s sarcoma). Doctors don’t know the exact cell of origin. Recently, doctors have defined the disease to include a family of tumors. This includes the Ewing’s sarcoma of bone or soft tissue, primitive neuroectodermal tumor (PNET), and Askin tumor of chest wall. Sometimes these tumors are called small blue cell (round cell) tumors. They are named for the way they look under a microscope.

Compared with other cancers, all malignant bone tumors are rare. Among malignant bone tumors in children and young adults, Ewing’s sarcoma is the second most common. It occurs in 1.7 per million to 2.7 per million children who are younger than 15 years old. There is no known cause.

First a doctor uses imaging studies to diagnose a bone tumor. These include X-rays and MRI (magnetic resonance imaging), CT (computed tomography) and bone scans. The doctor confirms the diagnosis by taking a piece of tissue to look at under a microscope (biopsy). This may be done in an operating room or X-ray department.

Then, special tests can help the doctor diagnose Ewing’s sarcoma. The hallmark is an abnormality in the cell’s chromosomes. Genetic material is mismatched. Chromosomes #11 and #22 are affected.

More tests (blood tests, lung CT scan, bone scan, and bone marrow biopsy) are needed to show the extent of disease. This process is known as “staging”. Tests can show if cancer has spread to other sites. This can include the lungs or bone marrow. The part of the body where the first tumor develops is called the “primary” site. Any parts of the body where it spreads are called “metastatic” sites.

Risk Factors/Prevention

There are no known risk factors for developing Ewing’s sarcoma. There is no known genetic link. There is no means of prevention either. The tumor does not develop as a result of any dietary, social or behavioral habits. Parents of affected children should know that there is nothing they could have done to prevent the tumor.


There is usually pain and/or swelling at the affected site. But the tumor may be present for many months before it becomes large enough to cause pain and swelling. Injuries are not a known cause—but injury may draw attention to a tumor. A bone weakened by disease may break after a minor injury. Ewing’s sarcoma usually affects the long bones. These include the thighbone (femur), shinbone (tibia) and upper arm (humerus) bone. The bones of the pelvis may also be affected.

Treatment Options

Doctors in many specialties help treat Ewing’s sarcoma. These include orthopaedic surgical oncologists, pediatric or adult medical oncologists, radiation oncologists, pathologists and radiologists. Most patients are treated at major hospital institutions or cancer centers. The main treatments are:

  • Chemotherapy. This is used to kill the primary tumor and any unknown microscopic spread.
  • Surgery. This is used to remove the primary tumor, and occasionally metastatic lesions. If necessary, surgery can also rebuild the limb or body part.
  • Radiation.This is used to lower the chance of the primary tumor coming back (recurring) or may be used instead of surgery at sites where surgery is too risky or complicated.
    Ewing’s sarcoma is usually diagnosed as a primary bone tumor without evidence of spread elsewhere. Even if tests to do not show spread, the treatment strategy assumes that a very small amount of spread (micrometastatic disease) has already happened.


Chemotherapy uses multiple medications. The most common agents are vincristine (Oncovin®), dactinomycin (actinomycin D®), cyclophosphamide (cytoxan®), and doxorubicin (adriamycin®). Recent evidence shows the addition of ifosfamide (Ifex®) and etoposide (VePesid®, VP-16) helps. The chemotherapy is given through an indwelling central venous catheter. This is placed just before treatment is started. Chemotherapy is done in cycles. It uses combinations of the various drugs. The time between cycles lets the blood cell count recover. This includes white blood cells and platelets. The drugs depress them. The patient will lose their hair. Various medications can lessen other side effects. These include nausea, mouth sores and fevers.

It generally takes close to one year to finish all the cycles of chemotherapy, with surgery and/or radiation. A doctor will look at the effect of chemotherapy. He or she will evaluate the number of cells killed in the tumor after it has been removed. This happens following several cycles of chemotherapy that may shrink the tumor, (figures 2 and 3). Many advances in chemotherapy have been made through knowledge gained by placing patients in clinical trials. Your doctor can tell you more. A physician may request permission to enroll a patient in a specific clinical trial.


Both surgery and radiation are effective treatments for the primary tumor. Many surgeons remove the tumor when doing so will not cause a major loss of function of the body part involved. Many doctors use radiation treatment only when a tumor cannot be removed completely or without the patient losing function.

The surgeon can reconstruct the bone, joint or soft tissue site. He or she may use use bone grafts, artificial joints, or a combination. The goal is to restore the body part so the patient can do their normal everyday activities. Strenuous or athletic activities are likely to cause too much stress or wear on the reconstruction.

Some patients may need more operations to keep the limb functioning for the rest of their life. Reconstruction of a bone in a growing child is a special challenge. As the child grows, multiple procedures are needed to lengthen the reconstructed bone. Surgery and/or radiation can be done either before or during chemotherapy. Most centers will halt the chemotherapy sessions sometime during the first half of the treatments to complete the surgery/radiation. Chemotherapy is restarted once the wound site has healed enough. This is usually about 2 weeks to 3 weeks after surgery.

Depending on the site involved, the patient may need to limit weight bearing on the limb. Ongoing rehabilitation with physical therapy is needed to optimize function.

In many cases, doctors can avoid amputation by surgically removing the primary tumor. Rebuilding the bone and joints is then needed. It’s important to consider the risks and complications associated with the surgery. Infections, problems with prosthesis and wound healing are the most frequent concerns.


When radiation treatment is used, daily treatments are given over the course of many weeks. While the discomfort of surgery may be avoided, there are risks, however, associated with the radiation including:

  • skin damage
  • muscle scarring and loss of joint flexibility
  • damage to nearby organs
  • loss of bone growth in growing children
  • secondary cancers caused by radiation
  • chronic swelling of an extremity
  • slow wound healing

Recently, more doctors are using surgery to remove the tumors when possible. Most physicians work as a team to tailor their recommendations of surgery and/or radiation to a patient’s specific situation.

Treatment outcome and success

The outcome for patients with Ewing’s sarcoma has improved a lot. This is thanks to improvements in chemotherapy, diagnostic imaging and reconstructive techniques. In general, two-thirds of patients without any demonstrable spread will survive at least five years after diagnosis with standard treatment. When tumors come back, it usually happens within the first few years after treatment. The absence of known spread is the most important factor in favor of being more likely to survive. Other factors include having excellent response to chemotherapy, primary tumors in the extremities instead of pelvis, and complete removal of the tumor.